Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 ...
-- Ono to Receive Exclusive License for All Therapeutic Uses of 5F9 in Select Asian Markets -- -- Forty Seven to Receive up to $120M in Combined Upfront and Potential Development and Commercial Milestone Payments, in Addition to Royalties on Net Sales -- …